Ovid Therapeutics to Participate in Upcoming September Investor Conferences
August 30, 2023 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
August 04, 2023 08:00 ET
|
Ovid Therapeutics Inc.
Completed single ascending dose (SAD) portion of Phase 1 trial evaluating OV329, a potential next-generation GABA-aminotransferase inhibitor Executed equity investment and initiated collaboration with...
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
August 01, 2023 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
June 28, 2023 08:00 ET
|
Ovid Therapeutics Inc.
Dr. Zhong Zhong joins Ovid as Chief Scientific Officer (CSO) and Dr. Manoj Malhotra assumes role as Chief Medical Officer (CMO) following the planned retirement of Dr. Claude NicaiseMeg Alexander...
Ovid Therapeutics Added to Russell 3000® Index
June 26, 2023 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
May 05, 2023 07:30 ET
|
Ovid Therapeutics Inc.
Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseasesLong-term data supporting soticlestat safety, tolerability and seizure-reduction...
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
May 01, 2023 06:00 ET
|
Ovid Therapeutics Inc.
Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton’s expertise in RhoA/ROCK2...
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
April 27, 2023 14:30 ET
|
Ovid Therapeutics Inc.
Interim 2-year findings show soticlestat appeared generally safe and well tolerated, consistent with prior studiesSustained reduction in frequency of drop seizures among Lennox-Gastaut patients and...
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
March 13, 2023 08:00 ET
|
Ovid Therapeutics Inc.
OV329 Phase 1 trial is progressing on trackAn IV formulation candidate suitable for future clinical trials has been achieved for OV350, one of several compounds from the Company’s KCC2 activator...